From Wikipedia, the free encyclopedia
  (Redirected from Mononuclear phagocyte)
Jump to: navigation, search
Monocytes, a type of white blood cell (Giemsa stained).jpg
monocytes under a light microscope from a peripheral blood smear surrounded by red blood cells
Latin monocytus
Code TH H2.
Anatomical terminology
3D Rendering of a Monocyte

Monocytes are a type of white blood cell, or leukocyte. They are the largest type of leukocyte and can differentiate into macrophages and they can acquire some features of dendritic cells. As a part of the vertebrate innate immune system monocytes also influence the process of adaptive immunity.

There are at least three types of monocytes in human blood.


Monocytes are amoeboid in appearance, and have a granulated cytoplasm.[1] Containing unilobar nuclei, these cells are one of the types of mononuclear leukocytes which shelter azurophil granules. The archetypal geometry of the monocyte nucleus is ellipsoidal; metaphorically bean-shaped or kidney-shaped, although the most significant distinction is that the nuclear envelope should not be hyperbolically furcated into lobes. Contrast to this classification occurs in polymorphonuclear leukocytes. Monocytes compose 2% to 10% of all leukocytes in the human body and serve multiple roles in immune function. Such roles include: replenishing resident macrophages under normal conditions; migration within approximately 8–12 hours in response to inflammation signals from sites of infection in the tissues; and differentiation into macrophages or dendritic cells to effect an immune response. In an adult human, half of the monocytes are stored in the spleen.[2] Monocytes are generally identified in stained smears by the large kidney shaped or notched nucleus. These change into macrophages after entering into appropriate tissue spaces, and can transform into foam cells in endothelium .


Monocytes are produced by the bone marrow from precursors called monoblasts, bipotent cells that differentiated from hematopoietic stem cells. Monocytes circulate in the bloodstream for about one to three days and then typically move into tissues throughout the body. They constitute between three and eight percent of the leukocytes in the blood. Half of them are stored as a reserve in the spleen in clusters in the red pulp's Cords of Billroth.[2] In the tissues, monocytes mature into different types of macrophages at different anatomical locations. Monocytes are the largest corpuscles in the blood.

Monocytes which migrate from the bloodstream to other tissues will then differentiate into tissue resident macrophages or dendritic cells. Macrophages are responsible for protecting tissues from foreign substances, but are also suspected to be important in the formation of important organs like the heart and brain. They are cells that possess a large smooth nucleus, a large area of cytoplasm, and many internal vesicles for processing foreign material.

Monocytes and their macrophage and dendritic-cell progeny serve three main functions in the immune system. These are phagocytosis, antigen presentation, and cytokine production. Phagocytosis is the process of uptake of microbes and particles followed by digestion and destruction of this material. Monocytes can perform phagocytosis using intermediary (opsonising) proteins such as antibodies or complement that coat the pathogen, as well as by binding to the microbe directly via pattern-recognition receptors that recognize pathogens. Monocytes are also capable of killing infected host cells via antibody-dependent cell-mediated cytotoxicity. Vacuolization may be present in a cell that has recently phagocytized foreign matter.

Many factors produced by other cells can regulate the chemotaxis and other functions of monocytes. These factors include most particularly chemokines such as monocyte chemotactic protein-1 and monocyte chemotactic protein-3 (CCL7); certain arachidonic acid metabolites such as Leukotriene B4 and members of the 5-Hydroxyicosatetraenoic acid and 5-oxo-eicosatetraenoic acid family of OXE1 receptor agonists (e.g., 5-HETE and 5-oxo-ETE); and N-Formylmethionine leucyl-phenylalanine and other N-formylated oligopeptides which are made by bacteria and activate the formyl peptide receptor 1.[3]

Microbial fragments that remain after such digestion can serve as antigens. The fragments can be incorporated into MHC molecules and then trafficked to the cell surface of monocytes (and macrophages and dendritic cells). This process is called antigen presentation and it leads to activation of T lymphocytes, which then mount a specific immune response against the antigen.

Other microbial products can directly activate monocytes and this leads to production of pro-inflammatory and, with some delay, of anti-inflammatory cytokines. Typical cytokines produced by monocytes are TNF, IL-1, and IL-12.

Monocyte subpopulations[edit]

There are at least three types of monocytes in human blood:[4]

  1. The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16 monocyte)
  2. The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[5]
  3. The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes).

While in man the level of CD14 expression can be used to differentiate non-classical and intermediate monocytes the slan cell surface marker was shown to give an unequivocal separation of the the two cell types.[6]

Ghattas et al. state that the "intermediate" monocyte population is likely to be a unique subpopulation of monocytes, as opposed to a developmental step, due to their comparatively high expression of surface receptors involved in reparative processes(including vascular endothelial growth factors type 1 and 2, CXCR4, and Tie-2) as well as evidence that the "intermediate" subset is specifically enriched in the bone marrow.[7] After stimulation with microbial products the CD14+CD16++ monocytes produce high amounts of pro-inflammatory cytokines like tumor necrosis factor and interleukin-12.

Said et al. showed that activated monocytes express high levels of PD-1 which might explain the higher expression of PD-1 in CD14+CD16++ monocytes as compared to CD14++CD16- monocytes. Triggering monocytes-expressed PD-1 by its ligand PD-L1 induces IL-10 production which activates CD4 Th2 cells and inhibits CD4 Th1 cell function.[8]

In mice, monocytes can be divided in two subpopulations. Inflammatory monocytes (Cx3CR1low, CCR2+, Ly6Chigh), which are equivalent to human classical CD14++ CD16 monocytes and resident monocytes (Cx3CR1high, CCR2neg, Ly6Clow), which are equivalent to human non-classical CD14low CD16+ monocytes. Resident monocytes have the ability to patrol along the endothelium wall in the steady state and under inflammatory conditions.[9][10][11] In man a monocyte crawling behavior, similar to the patrolling in mice, has been demonstrated both for the classical and the non-classical monocytes.[12]

Diagnostic use[edit]

A scanning electron microscope (SEM) image of normal circulating human blood. One can see red blood cells, several knobby white blood cells including lymphocytes, a monocyte, a neutrophil, and many small disc-shaped platelets.

A monocyte count is part of a complete blood count and is expressed either as a percentage of monocytes among all white blood cells or as absolute numbers. Both may be useful but these cells became valid diagnostic tools only when monocyte subsets are determined.


Monocytosis is the state of excess monocytes in the peripheral blood. It may be indicative of various disease states. Examples of processes that can increase a monocyte count include:

A high count of CD14+CD16++ monocytes is found in severe infection (sepsis)[13] In the field of atherosclerosis high numbers of the CD14++CD16+ intermediate monocytes were shown to be predictive of cardiovascular events in at risk populations.,[14][15]


Monocytopenia is a form of leukopenia associated with a deficiency of monocytes. A very low count of these cells is found after therapy with immuno-suppressive glucocorticoids.[16] Also, non-classical slan+ monocytes are strongly reduced in patients with hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), a neurologic disease associated with mutations in the macrophage colony-stimulating factor receptor gene.[6]

Dendritic cells[edit]

Monocytes can be used to generate dendritic cells in vitro by adding cytokines like Granulocyte Monocyte Colony Stimulating Factor (GM-CSF) and IL-4.[17]

Blood content[edit]

Reference ranges for blood tests of white blood cells, comparing monocyte amount (shown in green) with other cells.

See also[edit]


  1. ^ "Differentiation of monocytes. Origin, nature, and fate of their azurophil granules". J. Cell Biol. 50: 498–515. 1971. doi:10.1083/jcb.50.2.498. PMC 2108281free to read. PMID 4107019. 
  2. ^ a b Swirski, FK; Nahrendorf, M; Etzrodt, M; Wildgruber, M; Cortez-Retamozo, V; Panizzi, P; Figueiredo, J-L; Kohler, RH; Chudnovskiy, A; Waterman, P; Aikawa, E; Mempel, TR; Libby, P; Weissleder, R; Pittet, MJ (2009). "Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites". Science. 325 (5940): 612–616. doi:10.1126/science.1175202. PMC 2803111free to read. PMID 19644120. 
  3. ^ Sozzani, S; Zhou, D; Locati, M; Bernasconi, S; Luini, W; Mantovani, A; O'Flaherty, J. T. (1996). "Stimulating properties of 5-oxo-eicosanoids for human monocytes: Synergism with monocyte chemotactic protein-1 and -3". Journal of immunology (Baltimore, Md. : 1950). 157 (10): 4664–71. PMID 8906847. 
  4. ^ Ziegler-Heitbrock, L; et al. (2010). "Nomenclature of monocytes and dendritic cells in blood". Blood. 116 (16): e74–e80. doi:10.1182/blood-2010-02-258558. PMID 20628149. 
  5. ^ Ziegler-Heitbrock, L (2007). "The CD14+ CD16+ Blood Monocytes: their Role in Infection and Inflammation, Review". J Leukocyte Biology. 81 (3): 584–92. doi:10.1189/jlb.0806510. PMID 17135573. 
  6. ^ a b Hofer, Thomas P.; et al. (2015). "slan definded subsets of CD16 positive monocytes impact of granulomatous inflammation and M CSF receptor mutation". Blood. 126 (24): 2601–2610. doi:10.1182/blood201506651331. 
  7. ^ Ghattas; et al. (2013). "Monocytes in Coronary Artery Disease and Atherosclerosis. Where are we now?". Journal of the American College of Cardiology. 62: 1541–1551. doi:10.1016/j.jacc.2013.07.043. 
  8. ^ Said, Elias A.; et al. (2010). "PD-1 Induced IL10 Production by Monocytes Impairs T-cell Activation in a Reversible Fashion". Nature Medicine. 16: 452–9. doi:10.1038/nm.2106. 
  9. ^
  10. ^ Auffray, Cedric; Fogg, Darin; Garfa, Meriem; Elain, Gaelle; Join-Lambert, Olivier; Kayal, Samer; Sarnacki, Sabine; Cumano, Ana; Lauvau, Gregoire (2007-08-03). "Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior". Science. 317 (5838): 666–670. doi:10.1126/science.1142883. ISSN 0036-8075. PMID 17673663. 
  11. ^ Imhof, Beat A.; Jemelin, Stephane; Ballet, Romain; Vesin, Christian; Schapira, Marco; Karaca, Melis; Emre, Yalin (2016-08-01). "CCN1/CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation". Proceedings of the National Academy of Sciences: 201607710. doi:10.1073/pnas.1607710113. ISSN 0027-8424. PMID 27482114. 
  12. ^ Collison, Joanna L.; et al. (2015). "Heterogeneity in the Locomotory Behavior of Human Monocyte Subsets over Human Vascular Endothelium In Vitro". Journal of Immunology. 195 (3): 1162–1170. doi:10.4049/jimmunol.1401806. 
  13. ^ "The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients". Blood. 82 (10): 3170–6. November 1993. PMID 7693040. 
  14. ^ Heine, Gunnar H.; et al. (2008). "CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients". Kidney International. 73: 622–629. 
  15. ^ Rogacev, Kyrill S.; et al. (2012). "CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography". J Am Coll Cardiol. 60 (16): 1512–1520. doi:10.1016/j.jacc.2012.07.019. 
  16. ^ Fingerle-Rowson, G.; Angstwurm, M.; Andreesen, R.; Ziegler-Heitbrock, H.W.L. (1998). "Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy". Clin. Exp. Immunol. 112 (3): 501–506. doi:10.1046/j.1365-2249.1998.00617.x. PMC 1904988free to read. PMID 9649222. 
  17. ^ Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995). "Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products" (PDF). J. Exp. Med. 182 (2): 389–400. doi:10.1084/jem.182.2.389. PMC 2192110free to read. PMID 7629501. 

External links[edit]